Demyelinating and Inflammatory Diseases
- Covid-19 Vaccine Timing After Rituximab Can Decrease Hospitalization in MS
- Early DMT Initiation in MS Tied to Favorable Patient-Reported Outcomes
- Patients With MS Willing to Exchange Disease Progression for Fatigue Relief
- PIRA After First Demyelinating Attack May Lead to Unfavorable MS Prognosis
- Genetic Variant Panel Identified for Progressive Multifocal Leukoencephalopathy
- Accelerometers May Help Modify Physical Activity, Sedentary Time in MS
- Aberrations Identified in Gut Microbiota of Multiple Sclerosis Patients
- Briumvi Approved for Relapsing Forms of Multiple Sclerosis
- Air Pollutants Affect Risk for COVID-19 Pneumonia in Multiple Sclerosis
- Trigeminal Neuralgia Lesions Manifest Years Before Symptom Onset in MS
- OCT and VEP Tests May Effectively Monitor Patients With Secondary Progressive MS
- Obesity May Up Risk for Severe Disease, Poorer Outcomes in Multiple Sclerosis
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
